Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone.
Journal: Targeted oncology
Published: March 04, 2024
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma.
Journal: British journal of haematology
Published: September 01, 2022
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients.
Journal: Hematological oncology
Published: May 06, 2022
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.
Journal: Experimental hematology
Published: February 25, 2022
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma.
Journal: Leukemia & lymphoma
Published: November 25, 2021
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 17, 2019
Alopecia areata as a paraneoplastic syndrome of Hodgkin's lymphoma: A case report.
Journal: Molecular and clinical oncology
Published: November 29, 2013
Showing 1-7 of 7
Last Updated: 09/26/2026